

wherein: A is

(i)  $(\text{CH}_2)_n\text{-N-C(O)O-C}_{1-6}$  alkyl; and W is  $\text{C}_{1-6}$  alkyl; or  
W

(ii)  $(\text{CH}_2)_2\text{-N-}$  and forms a six membered ring  
Y

with B, said ring containing one nitrogen;

Y is

(a)  $\text{C}_{1-6}$  alkyl, or H;

(b)  $\text{C(O)-C}_{1-6}$  alkyl;

(c)  $\text{CH}_2\text{CH(OH)-CH}_2\text{-Z}$ , wherein Z is  $\text{C}_{1-6}$  alkyl or  $\text{O-C}_{1-6}$  alkyl;

(d) aryl; or

(e) heterocycle;

B is a single bond, OH or halo;

C is -OH,  $-\text{CH}_2-$  or forms a 5-membered lactone or lactam ring with D; and

**D is:** \_\_\_\_\_

(i) -OH, -CH<sub>2</sub>-halo, -CH(O)-, -COOH, -C(O)-O-C<sub>1-6</sub> alkyl, -(CH<sub>2</sub>)<sub>n</sub>, -CHOH-, wherein n is an integer and is 1, 2, or 3; or

(ii) forms a 5-membered lactone or lactam ring with C;


E is -H or -CH<sub>3</sub>; and

F is -OH,

or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier, said

**composition useful in the treatment of neoplastic diseases,**

with the proviso that the formula excludes noscapine of the structure



and a pharmaceutically acceptable carrier therefor.

C